Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

This phase III trial compares the effect of adding pirtobrutinib to the usual treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) to R-CHOP alone for the treatment of Richter transformation, which is when chronic lymphocytic leukemia or small lymphocytic lymphoma turns into large B-cell lymphoma, a more aggressive (faster-growing) form of lymphoma. Pirtobrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a ty

Trial Details

NCT ID

NCT07220187

Phase

PHASE3

Sponsor

SWOG Cancer Research Network

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Biospecimen Collection
Computed Tomography
Cyclophosphamide
Doxorubicin Hydrochloride
Echocardiography Test
Multigated Acquisition Scan

Locations (sample)

Irvine, California, United States|33.66946,-117.82311
Laguna Hills, California, United States|33.61252,-117.71283
Orange, California, United States|33.78779,-117.85311
Bloomington, Illinois, United States|40.4842,-88.99369
Canton, Illinois, United States|40.55809,-90.03512

Key Eligibility Criteria

Participants must have been diagnosed with Richter Transformation (RT) (CLL/small lymphocytic lymphoma \[SLL\] to LBCL)
Participants must have histologically or cytologically confirmed LBCL
Participants must have measurable disease determined by PET/CT or hematopathology (by morphology or flow cytometry) assessment within 42 days prior…
Participants must have staging PET/CT imaging performed within 42 days prior to registration

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →